CKD in Patients with Bilateral Oophorectomy : Clinical Journal of the American Society of Nephrology

Journal Logo

Original Articles: Chronic Kidney Disease

CKD in Patients with Bilateral Oophorectomy

Kattah, Andrea G.1; Smith, Carin Y.2; Gazzuola Rocca, Liliana3; Grossardt, Brandon R.2; Garovic, Vesna D.1; Rocca, Walter A.3,4

Author Information
Clinical Journal of the American Society of Nephrology 13(11):p 1649-1658, November 2018. | DOI: 10.2215/CJN.03990318
  • Free
  • Infographic
  • SDC

Abstract

Introduction

Estrogen has shown protective effects on the kidneys in both animal models and observational human studies. In particular, estrogen reduced glomerulosclerosis and glomerular permeability in ischemia-reperfusion injury in various animal models (1). In one model of sclerosis-prone mice, ovariectomy caused severe glomerulosclerosis and kidney dysfunction that was then corrected by continuous estrogen replacement (2,3). Younger women have a lower incidence of ESKD and slower progression of CKD than men; however, that advantage disappears after menopause (4–6). In addition, women may have a steeper increase in risk of cardiovascular and all-cause mortality for a given lower GFR or higher albuminuria compared with men (7). Observational studies of estrogen therapy in women have had variable results, with some studies showing beneficial effects of estrogen on markers of kidney dysfunction, such as albuminuria (8,9), and some other studies showing potential harm (10,11). These discrepant studies have had significant methodologic differences, including the ages of the women studied and the methods of assessing kidney function.

Women who undergo bilateral oophorectomy before natural menopause (often performed concurrently with hysterectomy) may have a particularly high risk of harm from prolonged estrogen deprivation (12). There is increasing evidence that premenopausal women who undergo bilateral oophorectomy may be at a higher risk for significant morbidity and mortality, particularly if they are younger than age 46 years old at the time of oophorectomy and do not receive adequate estrogen therapy (13–16). Studying this population of women who become acutely and surgically menopausal offers a unique opportunity to identify the precise onset of estrogen deprivation as well as adjust for the comorbidities and other possible confounders that are present at the index date (time of oophorectomy).

The long-term risk of CKD in women undergoing bilateral oophorectomy has not been explored previously. In this population-based cohort study, we evaluated the long-term risk of developing CKD in women who underwent bilateral oophorectomy compared with age-matched referent women without oophorectomy after adjusting for potential confounders, including cardiovascular, metabolic, and other chronic conditions present at the index date. We also assessed whether age at the time of oophorectomy and the use of estrogen therapy may modify this risk.

Materials and Methods

Cohort Definition and Comorbidities at Index Date

Women were identified as part of the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) as described extensively elsewhere (15–17). All of the data used for this study were derived from the medical records linkage system of the Rochester Epidemiology Project, which has been described elsewhere (18–21). All research activities were approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards. The cohort study included women who underwent bilateral oophorectomy or second unilateral oophorectomy from January 1, 1988 to December 31, 2007 and age-matched referent women from the same population. The oophorectomy had to be performed before the onset of menopause and before age 50 years old. The date of the surgical procedure was considered the index date, and simple random sampling was used to identify referent women from the same Olmsted County, Minnesota population born in the same year (±1 year) who had not undergone bilateral oophorectomy before the index date. Referent women did not have to be menopausal at the index date and remained eligible if they underwent bilateral oophorectomy after the index date.

Medical comorbidities present at the index date were electronically abstracted using selected International Classification of Diseases (ICD) diagnosis codes (ICD-8 or ICD-9) (22). Women needed to have at least two diagnostic codes in a given category separated by >30 days to avoid false positive diagnoses (17). Medical records were manually reviewed, and oophorectomy status was confirmed by trained study personnel (primarily L.G.R.). In addition, extensive clinical information was manually abstracted from the medical records, including demographic and reproductive characteristics and systemic estrogen therapy after the index date.

Assessment of CKD during Follow-Up

CKD was defined in two different ways—primarily using eGFR values and in a secondary analysis, using adjudicated diagnostic codes. The primary definition required an eGFR<60 ml/min per 1.73 m2 on at least two occasions >90 days apart (23). Serum creatinine (Cr) measurements were obtained from the electronic indexes of the Rochester Epidemiology Project and were available from the Mayo Clinic starting in 1994 and from Olmsted Medical Center in 1998, the two major providers of clinical care in Olmsted County, Minnesota. The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate eGFR from all electronically available, isotope dilution mass spectrometry-calibrated serum Cr levels (23). The onset of CKD was defined as the date of the second reduced eGFR measurement (meeting the time gap specified), and CKD was considered incident if the onset was on or after the index date. Women without eGFR results available were assumed to not have CKD.

In the secondary definition, a nephrologist (A.G.K.) reviewed and adjudicated the medical records of women who had received diagnostic codes for CKD. We first compiled a list of ICD diagnosis codes for CKD and then identified the women with two or more codes >30 days apart assigned at any time (before or after the index date). The complete medical records of these women were then reviewed, and the Kidney Disease: Improving Global Outcomes criteria for CKD stages 1, 2, and 3b–5 were applied (24). These criteria required an eGFR<45 ml/min per 1.73 m2 and/or the presence of markers of kidney damage (proteinuria or abnormal urinary sediment) over a 3-month period. We excluded stage 3a (defined as an eGFR of 45–60 ml/min per 1.73 m2 in the absence of proteinuria or abnormal urinary sediment), because during the pilot phase of the study, we noted that patients with stage 3a often went undiagnosed by providers and therefore, would have been missed by our targeted chart review. The rationale for adding this secondary definition was that CKD as defined by eGFR could be evaluated using laboratory values extracted electronically alone, whereas review of urine protein and sediment requires the clinical context for interpretation. Unfortunately, reviewing the medical records of the entire cohort was not feasible. We wanted to include CKD stages 1 and 2 in our analysis, because many of the studies suggesting a relationship between estrogen and the kidney evaluated proteinuria as an outcome.

Statistical Analyses

Each definition of CKD (eGFR and adjudicated diagnostic codes) was considered separately for the cohort analyses, and women with CKD onset before the index date were excluded from the corresponding outcome analysis (only incident outcomes were assessed). Women were followed from index date to the date of CKD onset, or they were censored at the earliest of death, time of last visit with a Rochester Epidemiology Project provider (lost to follow-up), or end of the study (December 31, 2014). We estimated unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) using Cox proportional hazards models, with age as the timescale. Cumulative incidence curves were estimated using the Kaplan–Meier method, and absolute risks were obtained from the Kaplan–Meier curves at 20 years after oophorectomy or index. Differences between the two cohorts were also measured using the absolute risk increase (ARI) or absolute risk reduction obtained by subtracting the two absolute risks.

The Kaplan–Meier estimates and Cox models were adjusted for potential confounders using inverse probability weights derived from a logistic regression model including 17 preexisting chronic conditions, years of education (≤12, 13–16, or >16), race (white versus nonwhite), body mass index (BMI; <30 versus ≥30 kg/m2), smoking status (current or former versus never), and age and calendar year at baseline (continuous) (25). Inverse probability weights were calculated overall and separately within each stratum to maximize the balance of characteristics at index date. Analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC), and tests of statistical significance were conducted at the two-tailed α-level of 0.05.

Additional details on cohort selection, assessment of kidney function, methods for statistical analyses in strata by age at index date and use of estrogen therapy, and methods for sensitivity analyses are reported in Supplemental Material. The strata by age reflect the definition of premature or early menopause (≤45 years old).

Results

Characteristics at Index Date

There were 1653 women in the bilateral oophorectomy cohort and 1653 age-matched referent women. The median length of follow-up was 14.5 years in women who underwent bilateral oophorectomy (interquartile range [IQR], 10.3–19.1) and 14.4 years in the referent cohort (IQR, 10.4–19.3). The characteristics at index date of women without prevalent CKD are summarized in Table 1. The majority of women in both cohorts were white; however, the percentage of whites was higher in the bilateral oophorectomy group. Women who underwent bilateral oophorectomy had higher BMIs and were less educated. The majority of women had some estrogen therapy after bilateral oophorectomy (n=1494, 90%), whereas only 479 referent women (29%) had estrogen therapy after the index date (Supplemental Material has more details).

Table 1. - Baseline characteristics of women without prevalent CKD in the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 from Olmsted County, Minnesota
Characteristic a Referent, n=1644 Bilateral Oophorectomy, n=1638
Age at oophorectomy, median (IQR) 44 (40–47) 44 (40–47)
Age at oophorectomy, yr, n (%)
 ≤45 1028 (63) 1024 (63)
 46–49 616 (37) 614 (37)
Calendar year of oophorectomy, n (%)
 1988–1992 317 (19) 317 (19)
 1993–1997 404 (25) 406 (25)
 1998–2002 549 (33) 546 (33)
 2003–2007 374 (23) 369 (23)
Race, n (%)
 White 1561 (95) 1596 (97)
 Black 29 (2) 18 (1)
 Asian 49 (3) 18 (1)
 Other 5 (0.3) 6 (0.4)
Years of education, n (%)
 <9 31 (2) 8 (0.5)
 9–12 443 (27) 517 (32)
 13–16 858 (52) 883 (54)
 >16 277 (17) 227 (14)
 Unknown b 35 (2) 3 (0.2)
Smoking status, n (%)
 Never 949 (58) 891 (54)
 Past 377 (23) 388 (24)
 Current 318 (19) 359 (22)
BMI, kg/m2, median (IQR) 25.9 (22.7–30.4) 27.2 (23.3–32.4)
BMI, kg/m2, n (%)
 <25.0 697 (42) 590 (36)
 25.0–29.9 486 (30) 477 (29)
 ≥30.0 438 (27) 571 (35)
 Unknown b 23 (1) 0 (0)
Hysterectomy, n (%)
 No 1482 (90) 24 (1)
 Before 162 (10) 156 (10)
 Concurrent with oophorectomy 1458 (89)
Oophorectomy indication, n (%) c
 No ovarian indication 968 (59)
 Benign condition 670 (41)
Concurrent hysterectomy indication, n (%) d
 Cancer 11 (0.7)
 Suspicion of cancer 308 (19)
 Bleeding 823 (50)
 Pain 588 (36)
 Fibroids or polyps 412 (25)
 Prolapse 335 (20)
 Endometriosis 200 (12)
 Other 225 (14)
IQR, interquartile range; BMI, body mass index; —, not applicable.
aWomen with prevalent CKD defined using eGFR were excluded from this table (nine referent women and 15 women who underwent bilateral oophorectomy).
bIn the regression models used to derive inverse probability weights, women with unknown education were assigned to the ≤12-year group, and women with unknown BMIs were assigned to the <30-kg/m2 group.
cThe indication was listed by the gynecologist in the medical record at the time of oophorectomy. Benign conditions include benign tumors, cyst, or endometriosis in either ovary. No ovarian indication includes women without a benign ovarian condition in either ovary. Historically, the terms “prophylactic,” “elective,” or “incidental” oophorectomy were used; however, we avoided these terms.
dThe indication was listed by the gynecologist in the medical record at the time of hysterectomy. Each woman may have more than one indication recorded.

Comorbidities Present at Index Date

There were significant differences in the burden of chronic diseases at index date in the two cohorts. Women who underwent bilateral oophorectomy were more likely to have previous diagnoses of depression, anxiety, substance abuse disorders, hyperlipidemia, hypertension, diabetes mellitus, cardiac arrhythmias, asthma, and chronic obstructive pulmonary disease. Supplemental Figure 1 shows the odds ratios and 95% CIs from case-control analyses for the 17 chronic conditions. Because of these differences at index date, inverse probability weighting was used in all adjusted analyses of CKD outcomes to balance the two cohorts with respect to these chronic conditions and other potential confounders. As an example, Supplemental Figure 2 shows the adjustments obtained in the overall sample and the stratum ≤45 years old at index date (using the eGFR-based definition of CKD; other results are not shown).

Primary Analyses: CKD Defined Using eGFR

Figure 1 shows the number of women in each cohort who developed CKD using the eGFR-based definition. The median eGFR level before and closest to the index date was slightly lower in women who underwent bilateral oophorectomy (95.6 ml/min per 1.73 m2; IQR, 82.7–105.7) than in referent women (96.9 ml/min per 1.73 m2; IQR, 83.9–106.5; P=0.003). There were 15 women in the bilateral oophorectomy cohort and nine women in the referent cohort with prevalent CKD at the index date (Supplemental Figure 1). After the index date, 211 women in the bilateral oophorectomy cohort and 131 women in the referent cohort developed incident CKD (unadjusted HR, 1.67; 95% CI, 1.35 to 2.07) (Table 2, Figure 2). The HR remained significant after adjusting for education, race, BMI, smoking, age, calendar year, and the presence of 17 chronic conditions at index date using inverse probability weights (adjusted HR, 1.42; 95% CI, 1.14 to 1.77). The absolute risk of incident CKD 20 years after the index date was 20.2% (95% CI, 17.3% to 23.5%) in the bilateral oophorectomy cohort and 13.6% (95% CI, 11.2% to 16.4%) in the referent cohort (ARI, 6.6%). The HR was higher in women who underwent oophorectomy at age ≤45 years old (adjusted HR, 1.59; 95% CI, 1.15 to 2.19; ARI, 7.5%) compared with those at age 46–49 years old (adjusted HR, 1.33; 95% CI, 0.98 to 1.81; ARI, 6.1%). However, the HRs were not significantly different across the two strata. In women who underwent oophorectomy at age ≤45 years old, the HR was higher in women who did not take estrogen or stopped it before their 46th birthday (adjusted HR, 2.07; 95% CI, 0.72 to 5.92; ARI, 11.9%) compared with women who received estrogen through their 46th birthday (adjusted HR, 1.52; 95% CI, 1.05 to 2.20; ARI, 12.5%). However, the HRs were not significantly different across the two strata.

fig1
Figure 1.:
Incident CKD defined using eGFR values was more common in women who underwent bilateral oophorectomy. Plasma or serum creatinine (Cr) tests were extracted from the Rochester Epidemiology Project electronic indexes (available back to 1994 from the Mayo Clinic and back to 1998 from the Olmsted Medical Center). eGFR was calculated from Cr values using the Chronic Kidney Disease Epidemiology Collaboration equation. CKD was defined as eGFR values <60 ml/min per 1.73 m2 on two occasions >90 days apart. CKD present at the index date was considered prevalent, and CKD that developed on or after the index date was considered incident.
Table 2. - Associations of oophorectomy with incident CKD defined by eGFR (primary analyses)
Chronic Condition and Strata Bilateral Oophorectomy Referent Women Unadjusted Models Adjusted Models a
N at Risk Person-yr N of Events Absolute Risk, % (95% CI) b N at Risk Person-yr N of Events Absolute Risk, % (95% CI) b Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Primary analyses
 Overall 1638 22,723 211 20.2 (17.3 to 23.5) 1644 22,967 131 13.6 (11.2 to 16.4) 1.67 (1.35 to 2.07) <0.001 1.42 (1.14 to 1.77) 0.002
 Age ≤45 yr 1024 14,439 110 17.6 (14.2 to 21.7) 1028 14,373 60 10.1 (7.6 to 13.4) 1.88 (1.38 to 2.56) <0.001 1.59 (1.15 to 2.19) <0.01
  ET>45 yr c 638 7795 75 25.0 (19.1 to 32.3) 597 7298 45 12.5 (8.9 to 17.5) 1.58 (1.10 to 2.27) 0.01 1.52 (1.05 to 2.20) 0.03
  No ET or ≤45 yr 177 1613 17 27.0 (13.5 to 49.6) 161 1628 6 15.1 (4.6 to 43.2) 2.87 (1.15 to 7.21) 0.02 2.07 (0.72 to 5.92) 0.18
 Age 46–49 yr 614 8283 101 25.4 (20.2 to 31.6) 616 8593 71 19.3 (14.9 to 24.8) 1.50 (1.11 to 2.03) <0.01 1.33 (0.98 to 1.81) 0.07
  ET>49 yr d 440 5622 71 29.0 (22.5 to 36.9) 422 5592 56 25.9 (19.3 to 34.4) 1.30 (0.92 to 1.85) 0.14 1.18 (0.83 to 1.69) 0.36
  No ET or ≤49 yr 152 1408 20 39.5 (21.3 to 65.1) 153 1485 12 25.2 (11.7 to 49.3) 1.73 (0.85 to 3.52) 0.13 1.34 (0.65 to 2.77) 0.43
First set of sensitivity analyses e
 Overall 1230 15,290 124 23.8 (18.0 to 31.0) 1132 14,399 60 13.7 (9.6 to 19.3) 2.02 (1.49 to 2.74) <0.001 1.61 (1.17 to 2.21) 0.003
 Age ≤45 yr 753 9440 64 21.4 (14.0 to 31.7) 677 8577 26 11.4 (6.5 to 19.9) 2.28 (1.45 to 3.59) <0.001 1.71 (1.05 to 2.78) 0.03
  ET>45 yr c 434 4714 38 40.0 (15.6 to 78.5) 383 4210 19 11.1 (6.3 to 19.2) 1.77 (1.02 to 3.07) 0.04 1.60 (0.90 to 2.83) 0.11
  No ET or ≤45 144 1178 12 12.5 (5.5 to 27.3) f 125 1105 4 6.3 (2.5 to 15.7) 2.85 (0.92 to 8.76) 0.07 1.54 (0.46 to 5.16) 0.49
 Age 46–49 yr 477 5850 60 28.4 (19.8 to 39.6) 455 5821 34 17.1 (11.1 to 26.0) 1.79 (1.18 to 2.72) <0.01 1.51 (0.98 to 2.31) 0.06
  ET>49 yr d 330 3789 41 32.8 (21.8 to 47.4) 304 3615 26 11.9 (7.9 to 18.0) f 1.55 (0.95 to 2.53) 0.08 1.36 (0.81 to 2.27) 0.25
  No ET or ≤49 yr 127 1055 10 12.0 (5.9 to 23.4) f 119 1034 5 8.2 (3.7 to 17.8) f 2.01 (0.68 to 5.92) 0.20 1.32 (0.44 to 4.03) 0.62
Second set of sensitivity analyses g
 Overall 656 9860 68 14.4 (11.1 to 18.8) 888 12,829 55 8.8 (6.5 to 12.0) 1.46 (1.03 to 2.08) 0.03 1.41 (0.99 to 1.99) 0.06
 Age ≤45 yr 420 6452 37 14.1 (10.0 to 19.6) 592 8503 27 7.3 (4.7 to 11.1) 1.63 (1.00 to 2.67) 0.05 1.58 (0.97 to 2.59) 0.07
 Age 46–49 yr 236 3407 31 15.5 (10.1 to 23.3) 296 4326 28 12.0 (7.7 to 18.6) 1.30 (0.78 to 2.16) 0.32 1.27 (0.76 to 2.12) 0.36
95% CI, 95% confidence interval; ET, estrogen therapy.
aHazard ratios were calculated using Cox proportional hazards models with age as the timescale and adjusted using inverse probability weights derived from a regression model including 17 chronic conditions present at baseline, years of education (unknown, ≤12, 13–16, or >16), race (white versus nonwhite), body mass index (unknown or <30 versus ≥30 kg/m2), cigarette smoking (current or former versus never), age at baseline (continuous), and calendar year at baseline (continuous). These adjustments were performed separately in each stratum to maximize the balance at baseline. None of the interactions by age were significant.
bAbsolute cumulative risk at 20 years after bilateral oophorectomy (or index) calculated using the Kaplan–Meier method. The estimates were adjusted using inverse probability weights derived from a logistic regression model including 17 chronic conditions present at baseline, years of education (unknown, ≤12, 13–16, or >16), race (white versus nonwhite), body mass index (unknown or <30 versus ≥30 kg/m2), cigarette smoking (current or former versus never), age at baseline (continuous), and calendar year at baseline (continuous). These adjustments were performed separately in each stratum to maximize the balance at baseline.
cWomen who were taking ET on their 46th birthday after bilateral oophorectomy (only oral or transdermal). Women who developed CKD before their 46th birthday, died or were lost to follow-up before their 46th birthday, or had not reached age 46 years old as of December 31, 2014 were not included in the corresponding analysis. Follow-up for these analyses was started at age 46 years old. None of the interactions by ET were significant in the ≤45-years-old age stratum.
dWomen who were taking ET on their 50th birthday after bilateral oophorectomy (only oral or transdermal). Women who developed CKD before their 50th birthday, died or were lost to follow-up before their 50th birthday, or had not reached age 50 years old as of December 31, 2014 were not included in the corresponding analysis. Follow-up for these analyses was started at age 50 years old. None of the interactions by ET were significant in the 46- to 49-years-old age stratum.
eExcluding women with oophorectomy or index date before January 1, 1994 and women with no serum creatinine measurements available.
fThe absolute risk was reported at 15 years after bilateral oophorectomy (or index) rather than at 20 years, because the follow-up was shorter.
gExcluding women with any of the 17 chronic conditions at the index date or with onset of CKD defined by eGFR or adjudicated diagnostic codes before the index date.

fig2
Figure 2.:
Higher cumulative incidence of CKD by eGFR-based criteria (upper panels) and adjudicated diagnostic codes (lower panels) in women who underwent bilateral oophorectomy. Cumulative incidence curves estimated using the Kaplan–Meier method and adjusted using inverse probability weights are shown in red for the bilateral oophorectomy cohort and black for the referent cohort. The hazard ratios (HRs) and corresponding 95% confidence intervals were calculated using Cox proportional hazards models with age as the timescale and adjusted using inverse probability weights. Analyses are shown overall (left panels), for women age ≤45 years old at the index date (center panels), and for women age 46–49 years old at the index date (right panels).

A first sensitivity analysis limited to women with an index date in the years 1994–2007 (when electronic Cr measurements were available) and excluding 142 women who did not have any serum Cr measurements (19 from the bilateral oophorectomy cohort and 123 from the referent cohort) yielded even stronger associations (overall adjusted HR, 1.61; 95% CI, 1.17 to 2.21) (Table 2). In a second sensitivity analysis restricted to women without any chronic conditions at baseline (excluding 997 women from the bilateral oophorectomy cohort and 765 women from the referent cohort), the HR was significant in the unadjusted model (HR, 1.46; 95% CI, 1.03 to 2.08) but was not significant in the adjusted model (HR, 1.41; 95% CI, 0.99 to 1.99; ARI, 5.6%). The results were virtually unchanged from the primary analysis in a third sensitivity analysis, which censored 84 referent women who underwent bilateral oophorectomy after the index date but before age 50 years old (results not shown).

Secondary Analyses: CKD Defined Using Adjudicated Diagnostic Codes

Figure 3 shows the number of women in each cohort who developed CKD defined using the adjudicated diagnostic codes. CKD was present at the index date in 11 women in the bilateral oophorectomy cohort and six women in the referent cohort (Supplemental Figure 1). Incident CKD developed in 61 women who underwent bilateral oophorectomy (28 by eGFR and 33 by urine protein) and 43 referent women (25 by eGFR, 17 by urine protein, and one by abnormal urinary sediment; adjusted HR, 1.17; 95% CI, 0.79 to 1.74) (Table 3, Figure 2). The HR was also not statistically significant in a first sensitivity analysis restricted to women with no chronic conditions at baseline (adjusted HR, 1.25; 95% CI, 0.67 to 2.32) (Table 3). Similar results to the secondary analysis were observed in an additional sensitivity analysis that censored referent women who underwent bilateral oophorectomy after the index date but before age 50 years old (results not shown). The causes of CKD obtained from medical record abstraction are described in Supplemental Material.

fig3
Figure 3.:
Incident CKD defined using adjudicated diagnostic codes was more common in women who underwent bilateral oophorectomy. The electronic indexes of the Rochester Epidemiology Project were screened for a list of International Classification of Diseases (ICD) diagnosis codes for CKD (ICD-8 or ICD-9). The medical records for all women with at least two of these codes separated by >30 days were then reviewed by a nephrologist. CKD was defined as an eGFR<45 ml/min per 1.73 m2 or evidence of kidney damage (proteinuria or active urinary sediment) on at least two occasions >90 days apart. CKD present at the index date was considered prevalent, and CKD that developed on or after the index date was considered incident. aWe excluded CKD stage 3a, because it often went undiagnosed by the care providers. bStructural abnormalities without evidence of kidney dysfunction were not included (e.g., atrophic kidney, medullary sponge kidney, hydronephrosis, and partial or complete nephrectomy).
Table 3. - Associations of oophorectomy with incident CKD defined by adjudicated diagnostic codes (secondary analyses)
Chronic Condition and Strata Bilateral Oophorectomy Referent Women Unadjusted Models Adjusted Models a
N at Risk Person-yr N of Events Absolute Risk, % (95% CI) b N at Risk Person-yr N of Events Absolute Risk, % (95% CI) b Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Secondary analyses
 Overall 1642 23,467 61 5.3 (3.8 to 7.3) 1647 23,530 43 4.7 (3.3 to 6.6) 1.44 (0.98 to 2.12) 0.06 1.17 (0.79 to 1.74) 0.44
 Age ≤45 yr 1024 14,754 39 5.8 (3.9 to 8.6) 1028 14,542 26 4.4 (2.8 to 6.9) 1.50 (0.92 to 2.44) 0.10 1.20 (0.73 to 1.99) 0.48
  ET>45 yr c 644 8086 22 5.8 (3.3 to 9.8) 600 7459 19 7.8 (4.6 to 13.3) 1.07 (0.58 to 1.97) 0.84 0.97 (0.52 to 1.81) 0.92
  No ET or ≤45 176 1639 9 25.1 (10.7 to 52.3) 161 1644 2 3.4 (0.9 to 12.2) 4.70 (0.99 to 22.31) 0.05 2.08 (0.39 to 11.10) 0.39
 Age 46–49 yr 618 8713 22 4.7 (2.8 to 7.7) 619 8988 17 5.2 (3.0 to 8.9) 1.34 (0.71 to 2.53) 0.36 1.23 (0.64 to 2.35) 0.54
  ET>49 yr d 446 5959 14 5.4 (2.7 to 10.5) 425 5855 14 4.1 (2.3 to 7.1) 1.00 (0.47 to 2.10) 0.99 0.83 (0.39 to 1.78) 0.63
  No ET or ≤49 yr 155 1489 5 2.6 (0.9 to 7.2) 154 1599 3 4.4 (0.7 to 24.5) 1.80 (0.46 to 6.99) 0.40 1.20 (0.30 to 4.74) 0.80
Sensitivity analyses e
 Overall 656 10,113 22 4.2 (2.5 to 6.9) 888 13,004 19 3.7 (2.3 to 6.1) 1.37 (0.74 to 2.56) 0.31 1.25 (0.67 to 2.32) 0.48
 Age ≤45 yr 420 6565 14 4.5 (2.4 to 8.5) 592 8572 11 2.7 (1.4 to 5.2) 1.50 (0.68 to 3.30) 0.31 1.32 (0.60 to 2.94) 0.49
 Age 46–49 yr 236 3548 8 3.6 (1.6 to 7.9) 296 4432 8 6.0 (2.9 to 12.5) 1.15 (0.42 to 3.14) 0.78 1.11 (0.41 to 3.03) 0.84
95% CI, 95% confidence interval; ET, estrogen therapy.
aHazard ratios were calculated using Cox proportional hazards models with age as the timescale and adjusted using inverse probability weights derived from a regression model including 17 chronic conditions present at baseline, years of education (unknown, ≤12, 13–16, or >16), race (white versus nonwhite), body mass index (unknown or <30 versus ≥30 kg/m2), cigarette smoking (current or former versus never), age at baseline (continuous), and calendar year at baseline (continuous). These adjustments were performed separately in each stratum to maximize the balance at baseline. None of the interactions by age were significant.
bAbsolute cumulative risk at 20 years after bilateral oophorectomy (or index) calculated using the Kaplan–Meier method. The estimates were adjusted using inverse probability weights derived from a logistic regression model including 17 chronic conditions present at baseline, years of education (unknown, ≤12, 13–16, or >16), race (white versus nonwhite), body mass index (unknown or <30 versus ≥30 kg/m2), cigarette smoking (current or former versus never), age at baseline (continuous), and calendar year at baseline (continuous). These adjustments were performed separately in each stratum to maximize the balance at baseline.
cWomen who were taking ET on their 46th birthday after bilateral oophorectomy (only oral or transdermal). Women who developed CKD before their 46th birthday, died or were lost to follow-up before their 46th birthday, or had not reached age 46 years old as of December 31, 2014 were not included in the corresponding analysis. Follow-up for these analyses was started at age 46 years old. None of the interactions by ET were significant in the ≤45-years-old age stratum.
dWomen who were taking ET on their 50th birthday after bilateral oophorectomy (only oral or transdermal). Women who developed CKD before their 50th birthday, died or were lost to follow-up before their 50th birthday, or had not reached age 50 years old as of December 31, 2014 were not included in the corresponding analysis. Follow-up for these analyses was started at age 50 years old. None of the interactions by ET were significant in the 46- to 49-years-old age stratum.
eExcluding women with any of the 17 chronic conditions at index date or with onset of CKD defined by eGFR or adjudicated diagnostic codes before the index date.

Discussion

We found that premenopausal women who underwent bilateral oophorectomy before age 50 years old were at higher risk of developing CKD compared with a cohort of age-matched referent women. This population-based study offers several advantages over prior efforts to understand the association of menopause and estrogen therapy with kidney function, because we identified women who experienced an abrupt onset of menopause. This design allowed us to adjust for chronic conditions present at the time of menopause onset that may affect the risk of CKD. We found consistent elevations and patterns of risk using both definitions of CKD, with a notably higher risk of CKD in women ≤45 years old at the time of oophorectomy and women who did not receive estrogen therapy; however, our findings were not statistically significant using the adjudicated diagnostic codes, likely because of limited statistical power. Similarly, the statistical power may have been limited in some of the stratified analyses due to small numbers of events.

Animal models support the hypothesis that estrogen deprivation may have important direct harmful effects on kidney structure and function. Mesangial cells that are critical to the pathogenesis of glomerulosclerosis express both estrogen receptor subtypes (α and β) in mice and humans (26,27). Estrogen has been found to prevent the accumulation of extracellular matrix and decrease the synthesis of type 1 and type 4 collagen (26,28,29). Ovariectomy caused significant kidney dysfunction, accumulation of extracellular matrix, and glomerulosclerosis in one study of sclerosis-prone mice (2). In addition, glomerulosclerosis and albuminuria were both prevented by continuous estradiol administration in a subsequent study using the same mouse model (30).

Previous studies in women have suggested that women have a lower incidence of ESKD and slower progression of CKD before menopause than men (5,6). This observed sex difference is often attributed to the beneficial effects of estrogen on the kidney, because the sex difference attenuates after menopause. A post hoc analysis in the Modification of Diet and Renal Disease Study showed a slower decrease in GFR in women than in men with CKD, particularly in women younger than age 52 years old (6). However, the effect of sex was attenuated after the investigators adjusted the analyses for BP, proteinuria, and HDL. Therefore, the difference in progression may have been mediated by these intervening conditions rather than it being due to a direct effect of estrogen on kidney function.

At least three observational studies in women and a recent meta-analysis have suggested that estrogen therapy may be associated with a lower risk of albuminuria (8,9,31,32). Estrogen can stimulate the release of nitric oxide and cause vasodilation (33,34). Impaired vasodilation and endothelial dysfunction are seen in CKD, and there is mounting evidence that nitric oxide deficiency may be linked to acceleration of kidney damage (35). Loss of estrogen after bilateral oophorectomy may, therefore, affect kidney structure and function in several ways, and it may increase the risk of developing CKD.

One challenge in studying the effects of estrogen therapy in humans is that the age of a woman and the time since menopause are important factors (timing hypothesis). For example, although the Women’s Health Initiative clinical trials showed an overall higher risk of coronary heart disease with estrogen therapy (36), a post hoc analysis showed a trend toward reduced cardiovascular events in women who initiated hormone therapy closer to the time of menopause compared with those who initiated hormone therapy later (37). Similarly, a large Canadian study showed that hormone therapy in older women (age >66 years old) was associated with a greater rate of decline in eGFR compared with in nonusers (10). By contrast, we observed a higher risk of CKD after bilateral oophorectomy after adjusting for relevant comorbid conditions in our cohort of younger women. Our findings suggest that there may be a direct beneficial effect of estrogen on kidney function. This is further supported by our observation that women younger than age 46 years old at the time of oophorectomy and who did not take estrogen or stopped it before their 46th birthday had a higher HR.

Observational evidence continues to mount suggesting that women who undergo bilateral oophorectomy at a younger age, particularly those without adequate estrogen therapy, have a higher risk of long-term morbidity and mortality (13,38,39). Findings from the MOA-2 have recently shown a significant accumulation of multimorbidity after bilateral oophorectomy that may be in part ameliorated by estrogen therapy (15,16). Levine et al. (40) showed that bilateral oophorectomy may be associated with accelerated aging as measured by the DNA methylation level in blood and saliva, a biologic marker considered an “epigenetic clock.” These findings have prompted the suggestion that women who become prematurely menopausal after bilateral oophorectomy should be treated with hormone therapy at “replacement” doses of estrogen to protect cardiovascular, bone, and neurologic health and slow the pace of aging as opposed to the lowest possible dose to control symptoms (41). Our study suggests that the kidney may be an additional organ that can suffer from premature estrogen deprivation. The kidney damage may be due to a combination of direct effects of estrogen deprivation and secondary damage mediated by the accumulation of multimorbidity in other organs and systems (e.g., kidney damage secondary to hypertension or diabetes). It remains unknown whether the effects of exogenous estrogen are similar to the effects of endogenous estrogen. In addition, exogenous estrogen used as therapy may vary by composition, dose, and route of administration.

Our study has some limitations. First, our study focused on a single geographically defined United States population, and the observed associations may differ in other populations in the United States and worldwide. Second, we were only able to access serum Cr and urine protein measurements that were taken as part of routine clinical care; therefore, some women did not have any measurements. Women who underwent bilateral oophorectomy had more frequent Cr tests and medical visits than referent women after the index date. These differences were small in absolute terms, but they were statistically significant (because of the large sample size) (Supplemental Material). In our adjudication of diagnostic codes, we found that 85% of the women with incident CKD had urine protein and Cr values at baseline to confirm absence of CKD; however, the absence of CKD at baseline could not be confirmed for the remaining 15% of the women. We tried to define CKD using two sets of criteria, a more inclusive set of criteria on the basis of eGFR alone and a set of criteria on the basis of targeted chart review using diagnostic codes. We observed a similar pattern of risk in the predefined age and estrogen therapy strata using the two definitions.

In conclusion, women who undergo bilateral oophorectomy before natural menopause are at higher risk of CKD, as defined by reduced eGFR, after adjustments for potential confounding comorbidities. Therefore, women considering bilateral oophorectomy for the prevention of ovarian cancer, particularly those at ages ≤45 years old, need to be counseled regarding the potential risks of multimorbidity, which may include the risk of CKD. There is a trend toward conserving the ovaries at the time of hysterectomy unless there is a compelling indication to remove them; however, the practice continues (42–44). Adequate hormone therapy in this group of women is essential, but there are limited data regarding the correct dose and route of administration (41). In addition, although estrogen has been shown to have multiple beneficial effects on the kidney in animal models, human studies have had contradictory results. To resolve these contradictions, future studies of the effects of hormone therapy on kidney function should be guided by the timing hypothesis (i.e., the effects of estrogen vary with the age of women).

Disclosures

None.

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.03990318/-/DCSupplemental.

Acknowledgments

This study used the resources of the Rochester Epidemiology Project, which is supported by National Institute on Aging, National Institutes of Health (NIH) awards R01 AG034676 and R01 AG052425. This study was also supported by funds from the Mayo Clinic Research Committee (W.A.R.). W.A.R. was partly supported by NIH grants P50 AG044170, U01 AG006786, and P01 AG004875.

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Hutchens MP, Fujiyoshi T, Komers R, Herson PS, Anderson S: Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am J Physiol Renal Physiol 303: F377–F385, 201222622457
2. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ: Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 162: 1441–1448, 200312707027
3. Karl M, Berho M, Pignac-Kobinger J, Striker GE, Elliot SJ: Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: Modulation of the mesangial cell phenotype in vivo. Am J Pathol 169: 351–361, 200616877338
4. Silbiger S, Neugarten J: Gender and human chronic renal disease. Gend Med 5[Suppl A]: S3–S10, 2008
5. Kummer S, von Gersdorff G, Kemper MJ, Oh J: The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr Nephrol 27: 1213–1219, 201221766172
6. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. Nephrol Dial Transplant 13: 1430–1437, 19989641172
7. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium: Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: A meta-analysis. BMJ 346: f324, 201323360717
8. Schopick EL, Fisher ND, Lin J, Forman JP, Curhan GC: Post-menopausal hormone use and albuminuria. Nephrol Dial Transplant 24: 3739–3744, 200919574340
9. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE: The relationship between albuminuria and hormone therapy in postmenopausal women. Am J Kidney Dis 45: 1019–1025, 200515957130
10. Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, Zhang J, Hemmelgarn BR; Alberta Kidney Disease Network: Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 74: 370–376, 200818496507
11. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT; Prevention of Renal and Vascular End Stage Disease Study Group: Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161: 2000–2005, 200111525702
12. Jacoby VL, Vittinghoff E, Nakagawa S, Jackson R, Richter HE, Chan J, Kuppermann M: Factors associated with undergoing bilateral salpingo-oophorectomy at the time of hysterectomy for benign conditions. Obstet Gynecol 113: 1259–1267, 200919461420
13. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd: Survival patterns after oophorectomy in premenopausal women: A population-based cohort study. Lancet Oncol 7: 821–828, 200617012044
14. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr., Roger VL, Melton LJ 3rd, Rocca WA: Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16: 15–23, 200919034050
15. Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM: Accelerated accumulation of multimorbidity after bilateral oophorectomy: A population-based cohort study. Mayo Clin Proc 91: 1577–1589, 201627693001
16. Rocca WA, Gazzuola Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM: Bilateral oophorectomy and accelerated aging: Cause or effect? J Gerontol A Biol Sci Med Sci 72: 1213–1217, 201728329133
17. Rocca WA, Gazzuola Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Stewart EA, Mielke MM, Kantarci K, Miller VM: Cohort profile: The Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open 7: e018861, 201729162577
18. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA: Use of a medical records linkage system to enumerate a dynamic population over time: The Rochester Epidemiology Project. Am J Epidemiol 173: 1059–1068, 201121430193
19. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ 3rd, Rocca WA: Generalizability of epidemiological findings and public health decisions: An illustration from the Rochester Epidemiology Project. Mayo Clin Proc 87: 151–160, 201222305027
20. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd: History of the Rochester Epidemiology Project: Half a century of medical records linkage in a US population. Mayo Clin Proc 87: 1202–1213, 201223199802
21. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Pankratz JJ, Brue SM, Rocca WA: Data resource profile: The Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol 41: 1614–1624, 201223159830
22. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK: Defining and measuring chronic conditions: Imperatives for research, policy, program, and practice. Prev Chronic Dis 10: E66, 201323618546
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 200919414839
24. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825–830, 201323732715
25. Harder VS, Stuart EA, Anthony JC: Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods 15: 234–249, 201020822250
26. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ: Estrogen-related abnormalities in glomerulosclerosis-prone mice: Reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 160: 1877–1885, 200212000739
27. Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, Karl M: Expression and regulation of estrogen receptors in mesangial cells: Influence on matrix metalloproteinase-9. J Am Soc Nephrol 12: 241–251, 200111158214
28. Silbiger S, Lei J, Neugarten J: Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1. Kidney Int 55: 1268–1276, 199910200990
29. Silbiger S, Lei J, Ziyadeh FN, Neugarten J: Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol 274: F1113–F1118, 19989841504
30. Catanuto P, Doublier S, Lupia E, Fornoni A, Berho M, Karl M, Striker GE, Xia X, Elliot S: 17 Beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int 75: 1194–1201, 200919279558
31. Fung MM, Poddar S, Bettencourt R, Jassal SK, Barrett-Connor E: A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: The Rancho Bernardo Study. Menopause 18: 629–637, 201121326121
32. Kattah AG, Suarez MLG, Milic N, Kantarci K, Zeydan B, Mosley T, Turner ST, Ware EB, Kardia SLR, Garovic VD: Hormone therapy and urine protein excretion: A multiracial cohort study, systematic review, and meta-analysis. Menopause 25: 625–634, 2018
33. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO 3rd: The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 96: 2795–2801, 19979386140
34. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401–406, 19999927501
35. Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1–F9, 200817928410
36. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333, 200212117397
37. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465–1477, 200717405972
38. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113: 1027–1037, 200919384117
39. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE: Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol 121: 709–716, 201323635669
40. Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CD, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes TL, Horvath S: Menopause accelerates biological aging. Proc Natl Acad Sci U S A 113: 9327–9332, 201627457926
41. Faubion SS, Files JA, Rocca WA: When lowest dose for shortest amount of time does not apply. J Womens Health (Larchmt) 25: 416–417, 201627028370
42. Evans EC, Matteson KA, Orejuela FJ, Alperin M, Balk EM, El-Nashar S, Gleason JL, Grimes C, Jeppson P, Mathews C, Wheeler TL, Murphy M; Society of Gynecologic Surgeons Systematic Review Group: Salpingo-oophorectomy at the time of benign hysterectomy: A systematic review. Obstet Gynecol 128: 476–485, 201627500347
43. Rocca WA, Faubion SS, Stewart EA, Miller VM: Salpingo-oophorectomy at the time of benign hysterectomy: A systematic review. Obstet Gynecol 129: 202–203, 201728002288
44. Mahal AS, Rhoads KF, Elliott CS, Sokol ER: Inappropriate oophorectomy at time of benign premenopausal hysterectomy. Menopause 24: 947–953, 201728486247
Keywords:

Oophorectomy; estrogen; chronic kidney disease; cohort study; modifiable risk factor; accelerated aging; Incidence; Cohort Studies; Proportional Hazards Models; Multiple Chronic Conditions; Body Mass Index; glomerular filtration rate; Menopause; Ovariectomy; Premenopause; Estrogens; Renal Insufficiency, Chronic; Smoking

Copyright © 2018 by the American Society of Nephrology